Latest Purchase Adds to Greatbatch’s Design Stable

Greatbatch Inc. has acquired NeuroNexus Technologies for approximately $12 million in cash—including the assumption of debt and future considerations.

NeuroNexus, headquartered in Ann Arbor, Mich., is an active implantable medical device design firm specializing in developing and commercializing neural interface technology, components and systems for neuroscience and clinical markets.

According to a release from Greatbatch, its latest acquisition has “an extensive intellectual property portfolio, core technologies and capabilities to support the development and manufacturing of innovative neural interface devices across a wide range of functions,” including neuromodulation, sensing, optical stimulation and targeted drug delivery applications.

“We are very excited to have the NeuroNexus team join the QiG Group and Greatbatch family of companies. Together, we believe that we can research, design, develop and manufacture new world-class proprietary products and systems that will expand and potentially re-define the fields of cardiovascular and neuromodulation as we know them today,” said Thomas J. Hook, president and CEO of Greatbatch Inc. “Additionally, the strong alliance NeuroNexus has with the University of Michigan and the Michigan Economic Development Corporation should position us to expand our operations in the region.”

NeuroNexus, founded in 2004, employs approximately 25 associates in its Ann Arbor facility.

Clarence, N.Y.-based Greatbatch Inc. serves the medical device industry with three brands—Greatbatch Medical, Electrochem and the QiG Group. Greatbatch Medical develops and manufactures critical medical device technologies for the cardiac, neurology, vascular and orthopedic markets. Electrochem designs and manufactures battery and wireless sensing technologies for high-end niche applications in the energy, military, portable medical, and other markets. The QiG Group provides design and development of new medical devices.